艾隆科技(688329) - 2025 Q4 - 年度业绩

Financial Performance - The total operating revenue for 2025 reached RMB 452.49 million, an increase of 39.10% compared to RMB 325.29 million in the previous year[3] - The net profit attributable to the parent company was RMB 18.89 million, an increase of RMB 40.59 million from a net loss of RMB 21.70 million in the previous year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 8.21 million, an increase of RMB 46.30 million from a net loss of RMB 38.09 million in the previous year[6] - The earnings per share for the period was RMB 0.25, compared to a loss of RMB 0.29 in the previous year[3] - The weighted average return on equity increased to 2.48%, up by 5.27 percentage points from -2.79% in the previous year[3] Assets and Equity - The total assets at the end of 2025 were RMB 1,407.71 million, a year-on-year increase of 1.99%[6] - The equity attributable to the parent company was RMB 796.47 million, an increase of 5.77% compared to RMB 753.01 million at the beginning of the period[4] Operational Strategies - The company focused on optimizing product structure and increased sales of traditional Chinese medicine intelligent products and pharmaceutical information products, contributing to profit growth[7] - The company implemented cost reduction and efficiency enhancement measures, which improved cash collection and management capabilities, positively impacting profitability[7] Reporting Accuracy - There are no significant uncertainties affecting the accuracy of the performance report, and the data is preliminary and subject to final audit[10]